OTC Markets OTCPK - Delayed Quote USD
Astellas Pharma Inc. (ALPMY)
9.57
+0.03
+(0.31%)
At close: 3:58:52 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in JPY | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 1 | 16 | 15 |
| Avg. Estimate | 448.34B | 430.38B | 1.88T | 1.93T |
| Low Estimate | 431.57B | 430.38B | 1.72T | 1.77T |
| High Estimate | 463.2B | 430.38B | 1.92T | 2.01T |
| Year Ago Sales | 414.6B | 473.12B | 688.43B | 1.88T |
| Sales Growth (year/est) | 8.14% | -9.03% | 173.05% | 2.50% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ALPMY | -- | -- | -- | -- |
| S&P 500 | 6.94% | 4.52% | 8.32% | 14.18% |
Related Tickers
DSNKY Daiichi Sankyo Company, Limited
23.50
+1.34%
CHGCY Chugai Pharmaceutical Co., Ltd.
29.44
+1.73%
AMRN Amarin Corporation plc
11.18
+7.92%
OGN Organon & Co.
12.12
+5.48%
BAYN.DE Bayer Aktiengesellschaft
22.48
+1.70%
AZN AstraZeneca PLC
69.55
+1.52%
NVS Novartis AG
111.17
+0.94%
AMGN Amgen Inc.
279.84
+0.70%
GILD Gilead Sciences, Inc.
106.15
-0.22%
BMY Bristol-Myers Squibb Company
48.69
+0.33%